Recent Updates
Recently added Catalysts
MANE Positive Sentiment

Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Sunday, November 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Veradermics will hold a conference call on November 9, 2026, to discuss the topline results from Part B of its Phase 3 clinical trial, Study '302'. This trial evaluates VDPHL01, a treatment for males with mild-to-moderate pattern hair loss. The call will provide insights into the trial's findings and future implications.

Market Sentiment Analysis

POSITIVE FACTORS

  • Veradermics announced a conference call for results review.
  • The Phase 3 trial focuses on a proprietary treatment for hair loss.
  • The trial is registration-directed, indicating regulatory intent.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+59%
120-day peak, hindsight
Typical move
10.4%
average across 2 past catalysts
Cash runway
~167 mo
Low dilution risk
Lead asset
VDPHL01
Phase 3 · Androgenetic Alopecia

Full Press Release Details

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, November 9, 2026, at 8:00 am ET to review topline results from Part B of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘302’) evaluating VDPHL01, a proprietary, ext

Frequently Asked Questions

When is the Veradermics conference call scheduled?

The conference call is scheduled for November 9, 2026, at 8:00 am ET.

What is the focus of the Phase 3 trial?

The trial evaluates VDPHL01 for males with mild-to-moderate pattern hair loss.

What type of trial is Study '302'?

Study '302' is a randomized, double-blind, placebo-controlled trial.

What will be discussed during the call?

The call will review topline results from Part B of the trial.

ShareAdd on Google
Tags: MANE Veradermics VDPHL01 hair loss Phase 3 trial clinical trial
Last updated: Nov 8, 2026

Biotech snapshot

Cash runway
$820M liquidity · $5M/mo burn
~167 mo
Low dilution risk
Lead asset
VDPHL01Phase 3
Androgenetic Alopecia →

Catalyst track record

+59%
best trade around MANE's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MANE.

See every catalyst's timing & PoA →